Recombinant Rat Myelin-oligodendrocyte glycoprotein (Mog)

What is MOG and why is it important in neuroscience research?

Myelin Oligodendrocyte Glycoprotein (MOG) is a 28 kDa single-pass transmembrane glycoprotein belonging to the immunoglobulin superfamily. Despite comprising only 0.01-0.05% of CNS myelin proteins, MOG serves as a crucial autoantigen in multiple sclerosis research and experimental autoimmune encephalomyelitis (EAE) in various animal models. Its exclusive expression in the central nervous system by oligodendrocytes, specifically in the outer layer of the myelin sheath, makes it an ideal target for studying demyelinating disorders .

What is the typical structure of recombinant rat MOG used in research?

Recombinant rat MOG typically consists of the extracellular domain (amino acids 1-125) of the full protein. The molecular weight of recombinant rat MOG is approximately 14.2 kDa. Most commercially available and laboratory-produced preparations include a 6x His tag to facilitate purification. The protein is expressed in E. coli from the sequence corresponding to the extracellular domain of rat MOG (Accession #CAE84068) and purified from urea-denatured bacterial lysate using immobilized metal affinity chromatography (IMAC) .

How does rat MOG compare structurally to human and mouse MOG?

Rat MOG shares approximately 90% sequence homology with human MOG in the extracellular domain. The mouse MOG extracellular domain shares 95% amino acid sequence identity with rat MOG and 90% with human MOG. Despite this high homology, these proteins expose distinct conformational epitopes that affect antibody binding and pathogenicity. These differences are critical when designing cross-species studies or interpreting results from different animal models .

What expression systems are used for producing recombinant rat MOG?

E. coli is the predominant expression system for producing recombinant rat MOG. The protein is typically expressed with the sequence corresponding to the extracellular domain along with a His tag for purification purposes. The bacterial expression system allows for high yields of protein, though proper refolding is essential for maintaining conformational epitopes .

How is the quality and activity of recombinant rat MOG assessed?

Quality assessment of recombinant rat MOG includes:

• Purity evaluation using SDS-PAGE (typically >95% purity)

• Endotoxin testing using Limulus Amebocyte Lysate (LAL) quantitative kinetic assay (should be <0.1 EU per 1 μg)

• Biological activity testing through induction of EAE in susceptible rodent strains

• Western blot analysis using MOG-specific antibodies such as monoclonal antibody 8-18C5

• ELISA for detecting proper folding and epitope exposure

What are the optimal storage conditions for maintaining recombinant rat MOG stability?

Recombinant rat MOG is typically supplied as a sterile, frozen solution (1 mg/ml) in 25 mM sodium acetate buffer (pH 4.0). For long-term storage, it should be kept at -80°C, and repeated freeze-thaw cycles should be avoided to maintain protein integrity and conformational epitopes. Some preparations may be lyophilized from a 0.2 μm filtered solution in PBS and reconstituted at 100 μg/mL in PBS before use .

What are the protocols for inducing EAE using recombinant rat MOG?

For EAE induction in rodents using recombinant rat MOG:

• Female DA rats or Lewis rats (7-9 weeks old) are typically used

• Animals are immunized subcutaneously at the tail base with 50-75 μg of rat MOG per animal

• Complete Freund's adjuvant is used as an immune stimulant

• EAE symptoms typically develop within 10-14 days, presenting as limp tail, hind limb weakness, hind limb paralysis, and weight loss

• Animals should be monitored daily for clinical signs of disease progression

How do different MOG isoforms affect experimental outcomes?

Different MOG isoforms (rat, human, or mouse) expose distinct conformational epitopes that significantly affect experimental outcomes:

• All MOG proteins can induce high antibody titers as detected by ELISA

• Only certain MOG isoforms (like human MOG) induce encephalitogenic antibodies in primed B cell-deficient mice

• Pathogenic antibodies bind specifically to glycosylated MOG and live oligodendrocytes

• Non-pathogenic antibodies may still bind recombinant MOG and deglycosylated MOG in myelin

• The epitope recognized by pathogenic antibodies may be conformation-dependent rather than linear sequence-dependent

This variability highlights the importance of carefully selecting the appropriate MOG isoform for specific research questions.

How do conformational epitopes of MOG influence antibody pathogenicity?

Conformational epitopes of MOG are critical determinants of antibody pathogenicity. Research has identified distinct epitopes exposed on different MOG isoforms:

• Some epitopes (recognized by mAb 8.18c5 and M26) are common to all MOG isoforms

• Other epitopes (recognized by Fab M3-24) are length-dependent but species-independent

• Some epitopes (recognized by Fab M3-8) are species-dependent

Only pathogenic antibodies bind to live oligodendrocytes and induce repartitioning of MOG into lipid rafts after cross-linking, leading to dramatic changes in oligodendrocyte morphology. This lipid raft redistribution appears to be a key mechanism in antibody-mediated demyelination .

What cellular mechanisms underlie MOG antibody-mediated demyelination?

The pathogenic mechanism of MOG antibody-mediated demyelination involves:

• Binding of antibodies to conformational epitopes on oligodendrocyte surface MOG

• Cross-linking of surface MOG leading to its rapid repartitioning from detergent-soluble to insoluble fractions with characteristics of lipid rafts

• Changes in phosphorylation status of at least 10 proteins following MOG redistribution

• Alterations in oligodendrocyte cytoarchitecture, including process retraction

• Changes in cytoskeletal stability leading to demyelination

These cellular events provide a biochemical mechanism linking in vivo observations with in vitro findings regarding demyelinating disease .

How can researchers differentiate between pathogenic and non-pathogenic anti-MOG antibodies?

Differentiating pathogenic from non-pathogenic anti-MOG antibodies requires multiple assays:

• Binding to live oligodendrocytes: Only pathogenic antibodies bind to the surface of live oligodendrocytes in culture

• Effect on oligodendrocyte morphology: Pathogenic antibodies, when cross-linked with secondary antibodies, induce dramatic morphological changes in oligodendrocytes

• MOG redistribution assay: Pathogenic antibodies cause repartitioning of MOG into detergent-insoluble fractions (lipid rafts)

• Glycosylation-dependent binding: Pathogenic antibodies specifically recognize glycosylated MOG

• In vivo transfer: Only pathogenic antibodies exacerbate EAE when transferred to animals with T-cell-mediated inflammation

What techniques are used to detect anti-MOG antibodies in experimental samples?

Multiple techniques are employed to detect and characterize anti-MOG antibodies:

• ELISA: Detects antibody binding to plate-bound MOG, providing quantitative titer information but not distinguishing pathogenic from non-pathogenic antibodies

• Western blot analysis: Detects antibody binding to denatured MOG, useful for epitope mapping but not reflecting binding to native conformations

• Cell-based assays: Using MOG-expressing cell lines to detect antibodies that recognize cell-surface, natively folded MOG

• Immunocytochemistry with live oligodendrocytes: Most physiologically relevant for detecting pathogenic antibodies

• In vivo transfer models: Gold standard for determining pathogenicity of MOG antibodies

How can researchers ensure proper folding of recombinant rat MOG for immunological studies?

Ensuring proper folding of recombinant rat MOG involves:

• Using optimized refolding protocols after purification from bacterial inclusion bodies

• Verifying proper disulfide bond formation in the immunoglobulin-like domain

• Confirming binding to conformation-specific antibodies like 8-18C5

• Assessing biological activity through pilot EAE induction experiments

• Analyzing oligodendrocyte binding capacity in cell culture systems

• Testing for the exposure of known conformational epitopes using panel antibodies with defined specificities

What factors influence variability in EAE induction using recombinant rat MOG?

Several factors contribute to variability in EAE induction:

• MOG preparation quality: Proper folding and conformational epitope preservation

• Animal strain differences: DA rats and Lewis rats show different susceptibilities and clinical manifestations

• Age and gender of animals: Female rats aged 7-9 weeks show optimal responses

• Adjuvant formulation: Complete Freund's adjuvant composition affects immune response intensity

• Immunization protocol: Injection site, volume, and technique influence disease development

• Housing conditions: Stress levels and microbiome can affect EAE susceptibility and severity

• Protein storage conditions: Repeated freeze-thaw cycles can compromise MOG conformational epitopes

How can researchers address inconsistent antibody responses to recombinant rat MOG?

To address inconsistent antibody responses:

• Verify protein quality using SDS-PAGE and Western blotting with 8-18C5 antibody

• Test multiple detection methods, as some antibodies may recognize conformational rather than linear epitopes

• Consider the glycosylation status of MOG, as some pathogenic antibodies specifically recognize glycosylated forms

• Use positive controls like the monoclonal antibody 8-18C5 for validation

• Ensure proper storage of both MOG protein and serum samples to maintain epitope integrity

• Compare results across different MOG isoforms (rat, human, mouse) to identify species-specific responses

How are MOG epitope mapping techniques evolving to better understand MS pathogenesis?

Advanced epitope mapping approaches include:

• Crystal structure analysis of MOG complexed with antibody fragments

• Use of recombinant MOG isoforms with specific mutations to identify critical binding residues

• Comparison of epitopes recognized by antibodies from different species and disease models

• Analysis of conformational epitopes using hydrogen-deuterium exchange mass spectrometry

• Computational modeling of antibody-antigen interactions to predict pathogenic epitopes

These approaches help differentiate between disease-relevant and non-pathogenic epitopes, potentially leading to more specific diagnostic tests and therapeutic interventions for MS .

What are the implications of MOG glycosylation for antibody recognition and pathogenicity?

MOG glycosylation significantly impacts antibody recognition and pathogenicity:

• Pathogenic antibodies preferentially bind glycosylated MOG while non-pathogenic antibodies may bind both glycosylated and deglycosylated forms

• Enzymatic deglycosylation of myelin MOG alters antibody binding profiles

• Glycosylation patterns may differ between species, affecting cross-reactivity of antibodies

• Post-translational modifications of MOG may create neo-epitopes that are targets of autoimmune responses

• Glycosylation may influence MOG's localization in lipid rafts and its susceptibility to antibody-mediated crosslinking

Understanding these glycosylation-dependent interactions may lead to more specific therapeutic approaches targeting pathogenic antibody responses in MS .